DataVXACS Applied Materials & InterfacesPaper
journal article·2022-08-03Open access

Redox-Unlockable Nanoparticle-Based MST1 Delivery System to Attenuate Hepatic Steatosis via the AMPK/SREBP-1c Signaling Axis

Yuhan Li, Jing-Jun Nie, Yuhui Yang, Jianning Li, Jiarui Li, Xianxian Wu, Xing Liu, Da-Fu Chen, Zhiwei Yang, Fu-Jian Xu, Yi Yang

ACS Applied Materials & Interfaces· Volume 14· Issue 30
Publisher pageOpen full text
Source abstract

Abstract

To date, few effective treatments have been licensed for nonalcoholic fatty liver disease (NAFLD), which a kind of chronic liver disease. Mammalian sterile 20-like kinase 1 (MST1) is reported to be involved in the development of NAFLD. Thus, we evaluated the suitability of a redox-unlockable polymeric nanoparticle Hep@PGEA vector to deliver MST1 or siMST1 (HCP/MST1 or HCP/siMST1) for NAFLD therapy. The Hep@PGEA vector can efficiently deliver the condensed functional nucleic acids MST1 or siMST1 into NAFLD-affected mouse liver to upregulate or downregulate MST1 expression. The HCP/MST1 complexes significantly improved liver insulin resistance sensitivity and reduced liver damage and lipid accumulation by the AMPK/SREBP-1c pathway without significant adverse events. Instead, HCP/siMST1 delivery exacerbates the NAFLD. The analysis of NAFLD patient samples further clarified the role of MST1 in the development of hepatic steatosis in patients with NAFLD. The MST1-based gene intervention is of considerable potential for clinical NAFLD therapy, and the Hep@PGEA vector provides a promising option for NAFLD gene therapy.
Source: openalex_inverted_index · Quality: baseline

Research context

PolymersNanomaterials

OpenAlex topics: Liver Disease Diagnosis and Treatment · Endoplasmic Reticulum Stress and Disease · Lipid metabolism and biosynthesis

SciVX discovery tags are terminology-based. OpenAlex topics are source-provided classifications.

Affiliations

School of Basic Medical Sciences, Ningxia Medical University, Yinchuan 750004, China

Beijing Engineering Research Center for Experimental Animal Models of Human Critical Diseases, Institute of Laboratory Animal Science, Chinese Academy of Medical Sciences (CAMS) & Comparative Medicine Centre, Peking Union Medical College (PUMC), Beijing 100021, China

Key Lab of Biomedical Materials of Natural Macromolecules (Ministry of Education), Beijing Laboratory of Biomedical Materials, Beijing University of Chemical Technology, Beijing 100029, China

Laboratory of Bone Tissue Engineering, Beijing Laboratory of Biomedical Materials, Beijing Research Institute of Traumatology and Orthopaedics, Beijing Jishuitan Hospital, Beijing 100035, China

Capital Medical University, Beijing 100035, China

Funding

Beijing Outstanding Young Talents · Chinese Academy of Medical Sciences · National Natural Science Foundation of China · Beijing Jishuitan Hospital Nova Program · Beijing Hospitals Authority Youth Programme

References (32)

Show source-provided references
1. 10.1002/hep.2936710.1002/hep.29367 ↗
2. 10.1002/hep.2843110.1002/hep.28431 ↗
3. 10.1038/s41591-018-0104-910.1038/s41591-018-0104-9 ↗
4. 10.1016/j.jcmgh.2019.04.00710.1016/j.jcmgh.2019.04.007 ↗
5. 10.1053/j.gastro.2020.01.05210.1053/j.gastro.2020.01.052 ↗
6. 10.1002/hep.2878510.1002/hep.28785 ↗
7. 10.1056/NEJMra150351910.1056/NEJMra1503519 ↗
8. 10.1021/acs.jafc.2c0074410.1021/acs.jafc.2c00744 ↗
9. 10.1016/j.jhep.2021.02.00510.1016/j.jhep.2021.02.005 ↗
10. 10.1172/JCI9346510.1172/JCI93465 ↗
11. 10.1016/S1875-5364(18)30074-810.1016/S1875-5364(18)30074-8 ↗
12. 10.2337/dbi18-002410.2337/dbi18-0024 ↗
13. Beysen C. · Diabetes, Obes. Metab. · 2021 · 23 · 70010.1111/dom.14272 ↗
14. 10.1038/srep3620910.1038/srep36209 ↗
15. 10.1007/s12072-020-10096-010.1007/s12072-020-10096-0 ↗
16. 10.1016/j.cell.2015.10.04410.1016/j.cell.2015.10.044 ↗
17. 10.1016/j.ccr.2008.02.01110.1016/j.ccr.2008.02.011 ↗
18. 10.1210/er.2017-0016710.1210/er.2017-00167 ↗
19. 10.1016/j.bbrc.2016.02.05910.1016/j.bbrc.2016.02.059 ↗
20. 10.3892/mmr.2021.1212610.3892/mmr.2021.12126 ↗
21. 10.1016/j.devcel.2018.12.02110.1016/j.devcel.2018.12.021 ↗
22. 10.1016/j.jconrel.2021.03.03010.1016/j.jconrel.2021.03.030 ↗
23. 10.1021/acs.chemrev.8b0040110.1021/acs.chemrev.8b00401 ↗
24. 10.1002/adma.20180157010.1002/adma.201801570 ↗
25. 10.2337/dc16-101710.2337/dc16-1017 ↗
26. 10.1172/JCI8601310.1172/JCI86013 ↗
27. 10.1172/JCI13416510.1172/JCI134165 ↗
28. 10.1016/j.biochi.2004.09.01810.1016/j.biochi.2004.09.018 ↗
29. 10.1172/JCI7361510.1172/JCI73615 ↗
30. 10.1073/pnas.141157111110.1073/pnas.1411571111 ↗
31. 10.1016/j.cmet.2013.11.01810.1016/j.cmet.2013.11.018 ↗
32. 10.1042/BJ2006049910.1042/BJ20060499 ↗